Story perspectives

Isomorphic Labs Secures $1.2B Series B for AI Drug Development

5/16/2026

Summary

Story summary

Isomorphic Labs secured $1.2 billion in Series B financing, the largest AI-drug discovery funding this year.
Thrive Capital led the round, which also included Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
The funding will refine the IsoDDE platform, expand globally, and move candidates into clinical trials in London, Lausanne and Cambridge, Massachusetts.
Isomorphic Labs leverages DeepMind’s AlphaFold, a 2024 Nobel-winning technology, and works with Johnson & Johnson, Novartis and Eli Lilly.

1 of 1

Story summary

Isomorphic Labs secured $1.2 billion in Series B financing, the largest AI-drug discovery funding this year.
Thrive Capital led the round, which also included Alphabet, GV, MGX, Temasek, CapitalG and the UK Sovereign AI Fund.
The funding will refine the IsoDDE platform, expand globally, and move candidates into clinical trials in London, Lausanne and Cambridge, Massachusetts.
Isomorphic Labs leverages DeepMind’s AlphaFold, a 2024 Nobel-winning technology, and works with Johnson & Johnson, Novartis and Eli Lilly.